You just read:

Pionyr Immunotherapeutics Completes $62 Million Series B Financing to Advance Antibody-based Therapeutics Targeting the Tumor Microenvironment

News provided by

Pionyr Immunotherapeutics, Inc.

Dec 13, 2017, 06:30 EST